Possibility of drug delivery due to hydrogen bonds formation in nanodiamonds and doxorubicin: molecular modeling
https://doi.org/10.17586/2220-8054-2018-9-3-370-377
Abstract
The possibility of drug delivery and retention in cells due to hydrogen bond formation between enriched nanodiamonds and highly toxic drugs (for example doxorubicin), is investigated by numerical simulation. Using molecular modeling by the density functional theory method with the B3LYP functional and the 6-31G(d) basic set, we analyze hydrogen bond formation and their influence on IR-spectra and structure of molecular complex which is formed due to interaction between doxorubicin and nanodiamonds enriched by carboxylic groups. Numerical modeling of carboxylated nanodiamonds and doxorubicin interaction is based on nanodiamond representation by a diamond-like nanoparticle with simpler structure. Enriched adamantane (1,3,5,7-adamantanetetracarboxylic acid) is used as an example of carboxylated diamond-like nanoparticle. Combined IR spectrum as imposing of IR spectra for doxorubicin and 1,3,5,7-adamantanetetracarboxylic acid various interaction positions is obtained. The combined IR spectrum demonstrates good agreement with experimental data. The obtained results demonstrate that there can be strong hydrogen bonds between doxorubicin and nanodiamond as one of basic mechanism for drug delivery and retention in cells.
About the Authors
A. N. Bokarev
Saratov State Technical University named after Yury Gagarin
Russian Federation
Russian Federation
Saratov
I. L. Plastun
Saratov State Technical University named after Yury Gagarin
Russian Federation
Russian Federation
Saratov
References
1. Nanotherapeutics: Drug Delivery Concepts in Nanoscience. Ed. by Lamprecht A. CRC Press, Taylor and Francis Group, Boca Raton, 2008, 292 p.
2. Gupta R.B., Kompella U.B. Nanoparticles Technology for Drug Delivery. N.-Y. Taylor & Francis Group, 2006, 403 p.
3. Popova N.R., Popov A.L., Shcherbakov A.B., Ivanov V.K. Layer-by-layer capsules as smart delivery systems of CeO2 nanoparticle based theranostic agents. Nanosystems: physics, chemistry, mathematics, 2017, 8 (2), P. 282–289.
4. Yakovlev R.Y., Solomatin A.S., et al. Detonation diamond a perspective carrier for drug delivery systems. Rus. J. Gen. Chem., 2014, 84 (2), P. 379–390.
5. Ho D., Wang C-H.K., Chow E.K-H. Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine. Science Advances, 2015, 1 (7), P. 1500439.
6. Shenderova O.A., McGuire G.E. Science and engineering of nanodiamond particle surfaces for biological applications (Review). Biointerphases, 2015, 10 (3), P. 030802.
7. Schrand A.M., Ciftan H.S.A., Shenderova O.A. Nanodiamond particles: properties and perspectives for bioapplications. Crit. Rev. Solid State Mater. Sci., 2009, 34, P. 18–74.
8. Solomatin A.S., Yakovlev R.Yu., et al. Antibacterial activity of Amikacin-immobilized detonation nanodiamond. Nanosystems: physics, chemistry, mathematics, 2017, 8 (4), P. 531–534.
9. Salaam A.D., Hwang P.T.J., et al. Nanodiamonds enhance therapeutic efficacy of doxorubicin in treating metastatic hormone-refractory prostate cancer. Nanotechnology, 2014, 25 (42), P. 425103.
10. Zhang X., Hu W., et al. A comparative study of cellular uptake and cytotoxicity of multiwalled carbon nanotubes, graphene oxide, and nanodiamond. Toxicol. Res., 2012, 1, P. 62–68.
11. Shugalei I.V., Voznyakovskii A.P., et al. Biological activity of detonation nanodiamond and prospects in its medical and biological applications. Russ. J. Gen. Chem., 2013, 83 (5), P. 851–883.
12. Liu K.K., Zheng W.W., et al. Covalent linkage of nanodiamondpaclitaxel for drug delivery and cancer therapy. Nanotechnology, 2010, 21, P. 1–14.
13. Toh T.-B., Lee D.-K., et al. Nanodiamondmitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells. Mol. Pharmaceutics, 2014, 11, P. 2683–2691.
14. Plastun I.L., Agandeeva K.E., Bokarev A.N., Zenkin N.S. Diamond-like nanoparticles influence on flavonoids transport: molecular modeling. Proc. SPIE, 2017, 103360K.
15. Adnan A., Lam R., et al. Atomistic simulation and measurement of pH dependent cancer therapeutic interactions with nanodiamond carrier. Mol. Pharmaceutics, 2011, 8, P. 368–374.
16. Petrioli R., Fiaschi A.I., et al. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone refractory prostate cancer. Cancer Treat. Rev., 2008, 34, P. 710-8.
17. Saltiel E., McGuire W. Doxorubicin (adriamycin) cardiomyopathy – a critical review. West J. Med., 1983, 139, P. 332–341.
18. Kohn W. Nobel Lecture: Electronic structure of matterwave functions and density functionals. Reviews of Modern Physics, 1999, 71 (5), P. 1253–1266.
19. Pople J. Nobel Lecture: Quantum chemical models. Reviews of Modern Physics, 1999, 71 (5), P. 1267–1274.
20. Frisch M.J., Trucks G.W., et al. Gaussian 09, Revision A.02. Wallingford CT, Gaussian Inc., 2009.
21. Fort R.C.Jr., Schleyers P. von R. Adamantane: Consequences of diamondoid structure. Chem. Rev., 1964, 64 (3) P. 277–300.
22. Ermer . Five-fold diamond structure of adamantane-1,3,5,7-tetracarboxylic acid. Journal of American Chemical Society, 1988, 110 (12), P. 3747–3754.
23. Iogansen A.V. IR Spectroscopy and Hydrogen Bond Energy Determination. Hydrogen Bond, Nauka, Moscow, 1981, P. 112–155 (in Russian)
Review
For citations:
Bokarev A.N., Plastun I.L. Possibility of drug delivery due to hydrogen bonds formation in nanodiamonds and doxorubicin: molecular modeling. Nanosystems: Physics, Chemistry, Mathematics. 2018;9(3):370-377. https://doi.org/10.17586/2220-8054-2018-9-3-370-377
Views:
4
Email this article 